One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases.
Van Voorhis WC, Hulverson MA, Choi R, Huang W, Arnold SLM, Schaefer DA, Betzer DP, Vidadala RSR, Lee S, Whitman GR, Barrett LK, Maly DJ, Riggs MW, Fan E, Kennedy TJ, Tzipori S, Doggett JS, Winzer P, Anghel N, Imhof D, Müller J, Hemphill A, Ferre I, Sanchez-Sanchez R, Ortega-Mora LM, Ojo KK.
Van Voorhis WC, et al.
Vet Parasitol. 2021 Jan;289:109336. doi: 10.1016/j.vetpar.2020.109336. Epub 2020 Dec 15.
Vet Parasitol. 2021.
PMID: 33418437
Free PMC article.
Review.
We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosporidium parvum), toxoplasmosis (pregnant sheep infected with Toxoplasma gondii), and neosporosis (pregnant sheep infected with Neospora cani …
We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosp …